Bruce A. Chabner, M.D.
Oncology
Dr.
Chabner is a Professor of Medicine at Harvard Medical School, Clinical
Director of the Cancer Center at Massachusetts General Hospital. With the
formation of the Dana-Farber/Harvard Cancer Center, he also has
responsibilities as Associate Director for Clinical Sciences of that
consortium, which includes the Massachusetts General Hospital, Brigham &
Women's Hospital, Dana-Farber Cancer Institute and Beth Israel Deaconess
Medical Center. Dr. Chabner was previously at the National Cancer Institute
("NCI"), where he participated in the training of clinical and research
fellows for 24 years and served for 13 years as permanent Director of the
Division of Cancer Treatment, NCI. From 1971 to 1989, he maintained an
active laboratory program in cancer pharmacology at the NCI, focusing on the
mechanism of action and resistance of antifolates and other antimetabolites,
and leading the development of paclitaxel (Taxol®). His research has
contributed significantly to the development of high dose chemotherapy
regimens and to standard therapies for lymphoma. He received an M.D., cum
laude, from Harvard Medical School.